Anavex Life Sciences Corp (AVXL)

[georgejjl]

we propose that traditional CNS drugs with sigma-1 receptor agonism are potential prophylactic drugs for the treatment of SARS-CoV-2-infected individuals.

Collectively, this study strongly suggests that the potent sigma-1-receptor agonist fluvoxamine could ameliorate inflammatory events (i.e., cytokine storm) associated with ER stress due to SARS-CoV-2 replication (Figs. 2, ?,33).

In this trial, fluvoxamine was selected due to its potent sigma-1-receptor agonism [16]. Given the role of the chaperone activity of the ER sigma-1 receptor agonist, it is possible that the potent sigma-1-receptor activity of fluvoxamine could contribute to beneficial actions in these patients. However, from the current trial, we cannot prove the contribution of fluvoxamine sigma-1-receptor agonism to beneficial actions in patients infected with SARS-CoV-2. Therefore, a clinical trial of fluvoxamine versus sertraline (or paroxetine) in patients infected with SARS-CoV-2 is needed to confirm the role of sigma-1-receptor agonism. Importantly, the advantages of fluvoxamine are safety, low cost, and oral administration.

raditional CNS compounds, such as fluvoxamine, donepezil, and ifenprodil, exhibit potent agonistic activity at the sigma-1 receptor. If we use these drugs to treat COVID-19-infected patients as quickly as possible after confirmation of SARS-CoV-2 infection, we might block or delay clinical deterioration. Now is the time to start clinical trials of sigma-1-receptor agonists in individuals infected with SARS-CoV-2, since these compounds have been used worldwide. Among these candidates, fluvoxamine is the most attractive drug for COVID-19 pandemic since it can be used from children to older adults.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785036/

Since Anavex's Blarcamesine and Anvex 3-71 are potent sigma 1 receptor agonists, they should be in trials to treat COVID-19.

Good luck and GOD bless,